ClinicalTrials.Veeva

Menu

Pencil Beam Scanning in Patients With Renal Tumors

Children's Hospital of Philadelphia (CHOP) logo

Children's Hospital of Philadelphia (CHOP)

Status and phase

Enrolling
Early Phase 1

Conditions

Wilms Tumor
Renal Tumor

Treatments

Other: Proton beam radiation using pencil beam scanning

Study type

Interventional

Funder types

Other

Identifiers

NCT03810651
17-014386

Details and patient eligibility

About

This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.

Full description

Patients with renal tumors including Wilms and clear cell sarcoma of the kidney (CCSK) are treated with multimodality therapy which may include surgery, chemotherapy, and radiation. While long-term disease control is excellent, these patients remain at risk for early and late toxicities partially from radiation. There have been no significant changes to traditional photon radiation fields, which encompass the post-operative bed, anterior abdomen, and vertebral body. Proton beam radiation using pencil beam scanning, which is characterized by Bragg peak dose deposition and high conformality of dose to target regions, is ideally suited to treat the retroperitoneum. This pilot study evaluates pencil beam scanning proton therapy (PBS-PT) to:

  • result in low acute gastrointestinal toxicity in patients receiving radiation therapy for renal tumors as measured by laboratory evaluations, clinician-assessed, and patient reported health related quality of life outcomes
  • decrease the duration of radiation therapy
  • compare doses to organs at risk (OARs) using PBS-PT as compared to traditional photon fields

Enrollment

28 estimated patients

Sex

All

Ages

Under 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Less than 30 years of age

  • Diagnosis

    a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including

    1. Any patient with favorable histology (FH), stage III disease
    2. Any patient with focal or diffuse anaplasia
    3. Any patient with CCSK
  • The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK

Exclusion criteria

  • Prior radiotherapy to the region of the study cancer
  • Chemotherapy administered for diagnosis of Wilms tumor or CCSK
  • Pregnant or breastfeeding

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

28 participants in 1 patient group

Renal tumors
Other group
Description:
Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
Treatment:
Other: Proton beam radiation using pencil beam scanning

Trial contacts and locations

1

Loading...

Central trial contact

Ratnakar Patti; Christine Hill-Kayser, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems